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Objective: The objective of this study was to examine the relationship between patient beliefs 
about medication use and their likelihood of discontinuing treatment prematurely. Associations 
of patient beliefs about medication with clinical psychopathology and their life satisfaction 
were also assessed.
Methods: This post-hoc analysis used data from a randomized, open label, 1-year trial of 
antipsychotics in the treatment of patients with schizophrenia or schizoaffective disorders 
(N = 664). Medication management including dosage adjustment and medication switching 
was at doctors’ discretion, reﬂ  ecting naturalistic treatment in usual clinical care settings. Early 
treatment discontinuation was deﬁ  ned as all-cause study drop out. Patient-reported beliefs about 
medication were assessed by Rating of Medication Inﬂ  uences (ROMI), degree of clinical psy-
chopathology was measured by Positive and Negative Syndrome Scale (PANSS), and patient 
quality of life was measured by Lehman Quality of Life Interview (LQLI).
Results: Patient perception of medication beneﬁ  t was the only strong predictor of treatment 
duration among the 5 underlying dimensions of medication inﬂ  uence. Higher level of perceived 
beneﬁ  cial effect of medication was associated with reduced risk of early treatment discontinua-
tion (Hazard ratio = 0.56, 95% Conﬁ  dence Interval [0.40, 0.79], p = 0.001). Patients with greater 
beliefs in the beneﬁ  cial effect of treatment also had better clinical psychopathology outcome 
and were more satisﬁ  ed with their quality of life and well-being.
Conclusion: Understanding the predictors of early treatment discontinuation in the care of 
schizophrenia patients is important for the development of interventions to improve treatment 
outcome. Current ﬁ  ndings suggest that patient perception of beneﬁ  cial effect of medication may 
be a critical factor in achieving treatment persistence and a satisfactory treatment outcome.
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Background
The duration of maintenance treatment of schizophrenia-related disorders is a critical 
determinant of a patient’s successful recovery. The consequences of sub-optimal 
antipsychotic treatment duration or poor treatment adherence include risk of relapse 
(Ayuso-Gutierrez and del Rio Vega 1997; Perkins 2002) and increased hospitalization 
(Ayuso-Gutierrez and del Rio Vega 1997; Perkins 2002) which may derail functional 
recovery. Despite the important role of persistence with medication, most patients 
do not stay in treatment with the initially prescribed medication and switch to other 
medication or discontinue treatment (Lieberman et al 2005; McEvoy et al 2006; Stroup 
et al 2006). In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) 
study of 1493 patients with schizophrenia, patients randomized to 5 different antipsy-
chotic drugs had all-cause discontinuation rates from 64% to 82% over an 18-month 
period (Lieberman et al 2005). Of these patients who discontinued their initial study 
medication, approximately 43% dropped out of the study opposed to approximately Patient Preferences and Adherence 2007:1 10
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57% who switched treatments and entered Phase 1b or 
Phase 2 of the study (Lieberman et al 2005; McEvoy et al 
2006; Stroup et al 2006, 2007).
There are many factors associated with poor treatment 
persistence. The Health Belief Model (HBM) suggests that 
patient likelihood to continue with medication intake is a 
product of an implicit and subjective assessment of the rela-
tive costs and beneﬁ  ts of the medicine in relation to personal 
goals and constraints (Becker and Maiman 1975; Fenton et al 
1997; Perkins 1999). In this model, patients are more likely 
to stay in treatment of medication regimen when they believe 
that their need for treatment and the beneﬁ  ts of treatment 
outweigh the negative aspects.
Previous studies have found association between poor 
treatment persistence and negative aspects of treatment, 
including exacerbation of symptoms (Liu-Seifert et al 2005) 
and a 2-fold increase in the risk of psychiatric hospitalization 
(Valenstein et al 2002). The impact of patient perception of 
medication beneﬁ  ts on treatment persistence has not been 
well characterized. It has been reported that perceived ben-
eﬁ  ts of medication have a greater inﬂ  uence on persistence 
levels than treatment adverse events (Perkins et al 2006). 
Psychotic patients who recognized positive effects of medica-
tion that were secondary to symptom relief were more likely 
to adhere to their treatment regimens.
The aim of the present study was to identify the speciﬁ  c 
aspects of patient perception of medication intake that are 
most inﬂ  uential for dropping out prior to completion of treat-
ment in a large, 1-year randomized, open-label clinical trial 
of antipsychotics in the treatment of patients with schizo-
phrenia-related disorders, in which medication management 
reﬂ  ected usual clinical practice. Patients could switch medi-
cations and dosage during the trial based on the decision of 
the treating clinician. Thus, study drop-out would primarily 
be due to patient decision to discontinue treatment. This study 
also examined the relationship between patient beliefs about 
medication taking and psychopathology and their functional 
outcome. A better understanding of the factors that promote 
patient acceptance and persistence with treatment may lead 
to interventions to improve the management of schizophrenia 
patients.
Methods
This was a post-hoc analysis of a randomized, open-label, 
1-year, multi-site effectiveness trial of antipsychotics in the 
treatment of patients with schizophrenia or schizoaffective 
disorder (HGGD). The study was conducted between May 
1998 and September 2002 at 21 sites across 15 US states. 
A brief description of the patient population and study design 
is provided here. Additional details can be found in the pri-
mary report of the trial (Tunis et al 2006).
Patient population
Male and female patients at least 18 years old who met Diag-
nostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV) criteria for schizophrenia, schizoaffec-
tive disorder, or schizophreniform disorder were screened 
for inclusion in this study. Eligible patients had a score of 
at least 18 on the Brief Psychiatric Rating Scale (BPRS1-7, 
extracted from the PANSS). A total of 664 individuals were 
entered into the study (olanzapine [229], conventionals [214], 
and risperidone [221]). All treatment groups were collapsed 
and analyzed as a pooled sample. Table 1 lists the patient 
demographics, diagnosis, baseline illness characteristics and 
symptom severity. Institutional review board approval was 
secured, and written informed consent was obtained from 
all participants.
Study design
This effectiveness study enrolled a heterogeneous group of 
patients with a variety of psychiatric and medical comorbidi-
ties, including substance abuse. The study was designed to 
reﬂ  ect usual clinical care of schizophrenia patients by leaving 
Table 1 Baseline patient characteristics
Variablea Overallb
Age, years, mean (SD)  42.8 (12.0)
Sex 
Female 244  (37%)
Male 420  (63%)
Race/Ethnicity 
Caucasian 361  (54%)
African American  224 (34%)
Other 79  (12%)
Primary psychiatric diagnosis 
Schizophrenia 431  (65%)
Schizoaffective disorder  228 (34%)
Schizophreniform disorder  5 (~1%)
Currently employed   128 (19%)
Age at 1st psychiatric hospitalization, yrs, mean (SD)  26.2 (9.5)
# of Previous episodes of schizophrenia, mean (SD)  6.8 (9.6)
Time in hospital (past yr) for mental/emotional problems  9.1 (34.1)
Days, mean (SD) 
Inpatient setting at trial entry  31 (5%)
PANSS total score, mean (SD)  86.9 (19.8)
LQLI satisfaction with social relations subscale, mean (SD)  13.9 (3.7)
Notes: avariables are presented as n (%) unless otherwise noted; bn = 664 for Age, sex, 
race/ethnicity, primary psychiatric diagnosis, currently employed, inpatient care setting, 
and PANSS; n = 584 for age at ﬁ  rst psychiatric hospitalization; n = 644 for previous epi-
sodes of schizophrenia; n = 650 for time spent in hospital; n = 592 for LQLI satisfaction.Patient Preferences and Adherence 2007:1 11
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all medication management decisions to the physicians, who 
could adjust dosages and switch medications according to 
their clinical discretion. Participants were randomly assigned 
to begin treatment with one of three open-label antipsychotic 
regimens: 1) olanzapine as ﬁ  rst-line treatment; 2) ﬁ  rst-line 
treatment with a maximum of two (consecutive) conven-
tional agents before a possible switch to olanzapine; and 3) 
risperidone as ﬁ  rst-line treatment. Choice of a particular 
conventional agent was made by the treating physician and 
was based on an individual’s clinical and treatment his-
tory. Initial dosing, titration, and dosing adjustments were 
determined by treating physicians, with instructions to con-
sider clinical indications, as well as most current product 
labeling and package insert recommendations. Switching 
antipsychotic agents was also at the discretion of treating 
physicians. The simultaneous use of two antipsychotics was 
restricted to the interval needed for any switch. Most other 
psychotropic and nonpsychotropic medications could be 
used concomitantly.
Outcome measures
Patients’ perception about their medication intake was mea-
sured with the modiﬁ  ed version of ROMI scale (Weiden et al 
1994). The ROMI scale is used to assess subjective reasons 
for medication compliance and noncompliance. The modiﬁ  ed 
version used in the trial consisted of 19 items, each scored 
on a scale from 1 to 3. Patients were shown 9 statements that 
might reﬂ  ect reasons for compliance and 10 statements with 
reasons for noncompliance, and were required to indicate 
the level of agreement between each statement and their 
own attitude toward medication on a 3-point scale: strong 
(3), mild (2), none (1). The ROMI was assessed at all post 
baseline visits, Visits 3 (2 weeks), Visit 4 (2 months), Visit 
5 (5 months), Visit 6 (8 months) and Visit 7 (1 year), but 
was not available at baseline.
The PANSS (Kay et al 1987) was used to assess psycho-
pathology. Five distinct symptom domains were assessed 
using PANSS factor scales (Davis and Chen 2001): posi-
tive symptoms, negative symptoms, disorganized thought, 
impulsivity/hostility, and anxiety/depression. PANSS was 
assessed at baseline and all post baseline visits.
The Lehman Quality of Life Interview (LQLI) was 
used at baseline and visits 4 (2 months), 5 (5 months), 
and 7 (1 year) to assess the life circumstances of patients 
in terms of what they actually do and experience (objec-
tive quality of life) and their feelings about these expe-
riences (subjective quality of life or life satisfaction) 
(Lehman 1988).
Medication persistence was deﬁ  ned as remaining in the 
study for the full 1 year regardless of the speciﬁ  c medication. 
Conversely, early treatment discontinuation was deﬁ  ned as 
dropping out of study prior to completion of the trial for 
any cause. It is important to note that patients could switch 
medications based on the decision of the treating clinician 
and remain in the study. Thus, in this study treatment/study 
drop-out would primarily be a patient decision.
Statistical methods
All analyses in the current study were performed by pooling 
the 3 randomized treatment groups together. A two-sided 
alpha level of 0.05 was used for test of signiﬁ  cance.
In order to identify the underlying dimensions of patient 
beliefs about medication intake, we conducted Principal 
Component Analysis (PCA) on ROMI. The factors were 
derived based on the first assessment time point for 
ROMI-visit 3 (2 weeks). Further factors analyses were also 
conducted at visit 4 (2 months), as well as for each of the ran-
domized treatment groups individually to test the robustness 
of the constructed factors. The number of factors extracted 
was determined based on the criteria of an eigenvalue of 1 or 
greater. The VARIMAX rotational method was applied to 
obtain orthogonal rotation of the factors. Cronbach’s coef-
ﬁ  cient alpha was used to measure internal consistency of the 
factors. Titles were assigned to each of the derived factors 
based on the clinical interpretation of the factors. The factor 
scores were created by averaging the items within each factor 
and were used to represent the factors.
To test the predictive value of the underlying dimensions 
of patient beliefs about medication intake on early treatment 
discontinuation, a Cox Regression model on time to early 
discontinuation was constructed with the derived ROMI fac-
tors as time-dependent covariates. Hazard Ratio (HR) and 
95% Conﬁ  dence Interval (CI) of HR, as well as the p-value 
based on the model, were obtained and reported.
The visit-wise mean scores of ROMI factors were given 
at visits 3 through 7 and the changes from visit 3 to visit 7 
were tested for signiﬁ  cance using Wilcoxon signed-rank test. 
Visit-wise mean scores in changes from baseline were given 
for the PANSS factors at visits 3 through 7 and for the LQLI 
subscales at visits 4, 5 and 7. Wilcoxon signed-rank tests were 
used for assessing the signiﬁ  cance of these changes. The cor-
relation of ROMI factors with PANSS factors were measured 
by Pearson’s correlation coefﬁ  cients at visits 3 through 7. 
The correlation of ROMI factors with LQLI subscales were 
measured by Pearson’s correlation coefﬁ  cients at visits 4, 5 
and 7. We also examined relationship between ROMI factors Patient Preferences and Adherence 2007:1 12
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and changes in PANSS factors at visits 3 through 7 using 
Pearson’s correlation coefﬁ  cients.
Results
Patient beliefs about medication
Five factors were extracted as the underlying dimensions of 
patient beliefs about medication intake based on the modi-
ﬁ  ed, 19-item version of ROMI scale using PCA: F1-Negative 
Aspects of Medication, F2-Denial of Illness, F3-Positive 
External Inﬂ  uence, F4-Perceived Medication Beneﬁ  t and 
F5-Stigma. Table 2 lists the ROMI items that loaded onto 
each of the 5 factors and their loadings. For each factor, the 
correlation between each of its items and the total of all items 
for that factor is given. Cronbach’s alphas based on all the 
items included in each factor are also provided in Table 2 to 
measure the internal consistency of each factor. To test the 
robustness of the derived factors, additional factor analyses 
were conducted for each of the randomized treatment groups 
as well as at different time points during the study and the 
resulting factors remained largely consistent.
Predictors of treatment discontinuation
Of the 5 underlying dimensions of patient beliefs about medi-
cation taking, perceived medication beneﬁ  t (composed of 
the perceived daily beneﬁ  t, fear of relapse, side effect relief, 
and fulﬁ  llment of life goals items) was the only signiﬁ  cant 
predictor of early treatment discontinuation (Table 3). A 
higher level of perceived beneﬁ  cial effect of medication was 
associated with reduced likelihood of early treatment discon-
tinuation (HR = 0.56, 95% CI [0.40, 0.79], p = 0.001). This 
result indicated that, at any given visit where patient beliefs 
were assessed, a higher level of perceived medication beneﬁ  t 
by one point, such as strong versus mild or mild versus none, 
was associated with 44% less risk of discontinuing from the 
study during the following visit.
Association with clinical outcome
There was a signiﬁ  cant negative correlation between per-
ceived medication beneﬁ  t and all of the 5 PANSS factors 
at 2 weeks, indicating a greater belief in medication beneﬁ  t 
was associated with a better state of clinical psychopathology 
(Table 4). This relationship persisted throughout the course 
of the 1-year study. No other ROMI factors were associ-
ated with all 5 psychopathology domains. Greater level of 
perceived medication beneﬁ  t was also found to be similarly 
and signiﬁ  cantly associated with greater improvement in 
symptoms as measured by changes in all of the 5 PANSS 
factors at 2 weeks, 2 months and 1 year.
Perceived medication beneﬁ  t was the only ROMI fac-
tor that showed signiﬁ  cant improvement during the study 
from 2 weeks to 1 year (p   0.001) (Figure 1). Since ROMI 
was only collected after baseline, it was not possible to 
assess changes in patient beliefs from baseline over the 
ﬁ  rst 2 weeks. All of the 5 PANSS factors had signiﬁ  cant 
Table 2 ROMI collapsed factors
ROMI factors  Loading of item   Corr w/ total of collapsed   Cronbach’s alpha
  on factor  factor items  including all items
Factor 1- Negative aspects of medication      0.74
NC10. No daily beneﬁ  t   0.73  0.52 
NC13. Interferes with life goals  0.68  0.58 
NC14. Distressed by side effects  0.74  0.60 
Factor 2-Denial of illness      0.72
NC11. Medications currently unnecessary  0.86  0.56 
NC12. Never was ill  0.77  0.56 
Factor 3-Positive external inﬂ  uence      0.72
C6. Positive relation with clinical staff  0.74  0.47 
C7. Outside positive opinion about taking medications  0.78  0.61 
C8. Outside opinion that current medication is better  0.75  0.56 
Factor 4-Perceived medication beneﬁ  t       0.70
C1. Perceived daily beneﬁ  t  0.78  0.54   
C2. Fear of relapse  0.72  0.50 
C3. Side effect relief  0.58  0.41 
C4. Fulﬁ  llment of life goals  0.72  0.52 
Factor 5-Stigma      0.64
NC15. Embarrassment/Stigma over med  0.83  0.47 
NC16. Change in appearance  0.73  0.47 
Abbreviation: ROMI, Rating of Medication Inﬂ  uences.Patient Preferences and Adherence 2007:1 13
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improvement from baseline at all time points throughout 
the study (p   0.001).
Association with quality of life
Patient beliefs about medication beneﬁ  t were signiﬁ  cantly 
correlated to most aspects of patients’ subjective feelings 
about their quality of life as measured by LQLI subscales 
at 2 months, the ﬁ  rst available visit for LQLI after baseline 
(Table 5). Similar patterns were observed at 5 months and 
1 year. The data suggested subjective domains of LQLI had 
greater association with perceived medication beneﬁ  t than 
objective domains as indicated by the magnitude of correla-
tion coefﬁ  cients.
Most LQLI subscales had significant improvement 
from baseline at all post baseline visits. Living situation 
was not signiﬁ  cantly improved until 1 year post treatment, 
and amount of money spent on self was not improved until 
5 months post treatment. Job, objective family contact, and 
social contact did not achieve signiﬁ  cant improvement from 
baseline at any time point.
Discussion
Patient perception of medication beneﬁ  ts was the only strong 
predictor of medication persistence among the 5 underlying 
dimensions of medication inﬂ  uences. Poor perception of 
medication beneﬁ  ts signiﬁ  cantly increased the likelihood 
of stopping treatment prematurely in the current 1-year study 
of medication management in usual clinical practice. Patients 
with greater beliefs in the beneﬁ  cial effect of treatment also 
had better clinical symptoms, experienced greater symptom 
improvement, and were more satisﬁ  ed with their quality of 
life and well-being.
Research on the impact of positive effect of medication 
as perceived by patients on treatment persistence has been 
Table 3 Predictors of early treatment discontinuation based on ROMI factors
  Hazard Ratio  95% Conﬁ  dence Interval  p value
ROMI factor 1  1.27  (0.91, 1.78)  0.16
Negative aspects of medication
ROMI factor 2  1.10  (0.77, 1.59)  0.60
Denial of illness
ROMI factor 3  0.87  (0.65, 1.18)  0.37
Positive external inﬂ  uence
ROMI factor 4  0.56  (0.40, 0.79)  0.001
Perceived medication beneﬁ  t
ROMI factor 5  1.30  (0.89, 1.89)  0.17
Stigma
Abbreviation: ROMI, Rating of Medication Inﬂ  uences.
Notes: Analysis based on Cox Regression model on time to early treatment discontinuation with ROMI factors as time-dependent covariates. Early treatment discontinu-
ation was deﬁ  ned as all-cause study discontinuation.
Table 4 Pearson’s correlation coefﬁ  cient between ROMI factors and PANSS factors at 2 weeks
Correlation coefﬁ  cients   PANSS   PANSS  PANSS    PANSS   PANSS 
(p value)  positive  negative  disorganized thought  hostility  depression
ROMI factor 1  −0.0986  −0.0685   −0.0776   0.0434   0.0457 
Negative aspects of medication  (0.018)  (0.102)  (0.064)  (0.300)  (0.275)
ROMI factor 2  0.0191  0.0095   −0.0122   0.0284   −0.0594 
Denial of illness  (0.649)  (0.822)  (0.772)  (0.499)  (0.157)
ROMI factor 3  0.0248   0.0764   0.0574   −0.0147   −0.0044 
Positive external inﬂ   uence  (0.549)  (0.065) (0.165)  (0.723) (0.915)
ROMI factor 4  −0.2496   −0.2695   −0.2202   −0.1884   −0.1878 
Perceived medication beneﬁ  t  ( 0.001) ( 0.001) ( 0.001) ( 0.001) ( 0.001)
ROMI factor 5  0.1113   0.0445   0.0639   0.2300   0.1584 
Stigma (0.007)  (0.281)  (0.121)  ( 0.001) ( 0.001)
Notes: Greater level of perceived medication beneﬁ  t was also found to be signiﬁ  cantly associated with greater improvement in symptoms as measured by changes in all of 
the 5 PANSS factors at 2 weeks, 2 months, and 1 year.
Abbreviations: ROMI, Rating of Medication Inﬂ  uences; Factor 1, 2, and 5: greater score indicates poorer compliance attitude; Factor 3 and 4: greater score indicates 
greater compliance attitude; PANSS, Positive and Negative Syndrome Scale; greater score indicates more severe symptom for all 5 factors.Patient Preferences and Adherence 2007:1 14
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limited. Medication persistence in the current study is similar 
to medication adherence in usual clinical practice since 
patients could switch medications while remaining in the 
study. Thus study/treatment discontinuation would primarily 
result from patient choice similar to adherence. Data from 
the current study suggest perceived beneﬁ  t from medication, 
including preventing relapse, relieving side effects, and ful-
ﬁ  lling life goals, was signiﬁ  cantly associated with psychiatric 
treatment persistence. This is consistent with a previous study 
of adherence in patients with schizophrenia, which reported 
that relapse prevention, prevention of symptom exacerbation, 
and daily beneﬁ  t of medication were the most frequently 
cited patient reasons for adherence (Lofﬂ  er et al 2003). It is 
also consistent with a recent qualitative examination of fac-
tors inﬂ  uencing medication adherence behavior in patients 
with schizophrenia, where medication efﬁ  cacy and attitudes 
toward medication were 2 of 5 clinically relevant themes 
identiﬁ  ed that inﬂ  uence medication adherence (Kikker et al 
2006). The ﬁ  ndings also concur with a recently published 
study on patients recovering from a ﬁ  rst episode of schizo-
phrenia (Perkins et al 2006). In that study, the likelihood of 
becoming medication non-adherent was greater in patients 
who believed medication was of low beneﬁ  t.
The Health Belief Model considers treatment nonadher-
ence as a decision made by patients after weighing medication 
beneﬁ  ts against risks and costs. Although previous research 
reported negative aspects of medication including adverse 
events as strong predictors of treatment nonadherence 
(Kampman and Lehtinen 1999), the present study did not 
ﬁ  nd a signiﬁ  cant association between negative aspects of 
medication and treatment persistence. These ﬁ  ndings are 
consistent with a previous study that reported the medication 
beneﬁ  ts were a more important factor of persistence than 
adverse events (Perkins et al 2006). Furthermore, another 
study found that poor treatment response along with wors-
ening symptoms was the most frequently given reason for 
discontinuing the treatment, which was substantially more 
common than discontinuation due to the poor tolerability of 
the medication (Liu-Seifert et al 2005).
More severe positive symptoms (Kamali et al 2006), deﬁ  -
cit symptoms (Freudenreich et al 2004), depression (Elboqen 
et al 2005), cognitive disorganization, and hostility (Marder 
et al 1983) have been previously associated with poor 
adherence attitude and behavior. The present study reported 
that better attitude toward medication adherence based on 
beliefs about medication beneﬁ  t was associated with better 
psychopathology in a broad spectrum of clinical symptoms. 
This positive adherence attitude was also found to be associ-
ated with greater improvement in clinical symptoms. These 
associations between greater beliefs in medication and better 
state of psychopathology, as well as greater improvement in 
psychopathology, persisted throughout the 1-year study.
In addition, the current study suggested patient attitude 
favoring treatment adherence based on perceived medication 
beneﬁ  t was positively associated with subjective quality of 
life and satisfaction with overall well-being. There has been 
limited knowledge of how quality of life and treatment adher-
ence relate to each other. While no direct relation could be 
discerned between subjective quality of life and adherence to 
medication by Puschner and colleagues (2006), other studies 
have found that subjective well-being and quality of life had 
a strong impact on treatment adherence (Coldham et al 2002; 
de Millas et al 2006). In addition, a recent analysis of obser-
vational data from German patients from the Schizophrenia 
Outpatient Health Outcomes study showed a strong asso-
ciation between subjective well-being and adherence with 
antipsychotic medication (Karow et al 2007).
The correlation between patient perception of medication 
beneﬁ  t and clinical symptom psychopathology and quality of 
life in the present study does not necessarily suggest the direc-
tion of causality. It is likely that perceived medication beneﬁ  t 
leads to motivation to adhere to treatment and ultimately 
to better clinical and functional outcomes. Alternatively, 
Figure 1 Post-baseline longitudinal course of ROMI factors from 2 weeks through 
1 year. Perceived medication beneﬁ  t was the only factor that signiﬁ  cantly improved 
over the course of treatment (2 weeks to 1 year: p   0.001).
F3-Positive external inﬂ  uence and F4-Perceived medication beneﬁ  t: reasons 
for compliance – 1 (none), 2 (mild), 3 (strong); greater score indicates greater 
compliance attitude.
F1-Negative aspects of medication, F2-Denial of illness and F5-Stigma: reasons 
for noncompliance – 1 (none), 2 (mild), 3 (strong); lower score indicates greater 
compliance attitude.
1
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patients may recognize the better psychopathology symptoms 
and better quality of life as the beneﬁ  cial effects of medi-
cation and establish beliefs in medication beneﬁ  ts. These 
results underline the important role of effective symptom 
control in patient’s perception of medication use and in turn 
their adherence and persistence to treatment. Further, the 
links between perceived medication beneﬁ  t and improved 
psychopathology and quality of life over the period of 1 year 
suggest the importance of continuous monitoring of patient 
symptoms, feelings about treatment, as well as satisfaction 
with life during treatment.
In the present study, ROMI data were not available at 
baseline; thus it was not possible to assess the early change 
in patient’s perception of medication use. A previous study 
found that patient perception of medication beneﬁ  t improved 
signiﬁ  cantly within a week of initiation of treatment and 
was a key driver of the improved adherence attitude in a 
population of acutely ill, noncompliant patients (Liu-Seifert 
et al 2007). The study also found that the acute improve-
ment in perceived medication beneﬁ  t was associated with 
the acute improvement in psychopathology. The present 
study on a relatively more stable and more compliant patient 
Table 5 Pearson’s correlation coefﬁ  cients between ROMI factors and LQLI subscales at 2 months
Correlation coefﬁ  cient  F1 negative   F2 denial   F3 positive   F4 perceived  F5 stigma
(p value)  aspects of medication  of illness  external inﬂ  uence  medication beneﬁ  t
Objective scale
Amount of money spent on self  0.027  0.0777  −0.0637  −0.0571  −0.0254
 (0.596)  (0.129)  (0.193)  (0.223)  (0.616)
Arrests  −0.0569  −0.0417 0.0332  −0.014 0.0132
   (0.204)  (0.352)  (0.441)  (0.734)  (0.766)
Current employment  0.0655  0.0199  −0.0523 0.0436  0.0824
   (0.143)  (0.656)  (0.222)  (0.290)  (0.063)
Daily activities  0.0095  −0.0019  −0.0306  −0.186  −0.0071
   (0.830)  (0.965)  (0.472)  ( 0.001) (0.872)
Family contact  −0.0264  −0.0892 0.2787  0.1783  0.0159
   (0.559 )  (0.048)  ( 0.001) ( 0.001) (0.722)
Financial adequacy  0.0316  0.0413  −0.0537  −0.139 0.0116
   (0.480)  (0.356)  (0.210)  ( 0.001) (0.795)
Social contact  0.009  −0.0654 0.1018  0.2242  0.0076
   (0.840)  (0.140)  (0.016)  ( 0.001) (0.863)
Victimization  −0.0166 0.042  −0.1304  −0.0656 0.0593
   (0.709)  (0.346)  (0.002)  (0.109)  (0.179)
Subjective scale
Daily activities  −0.1007 0.0206  0.1884  0.3237  −0.1176
   (0.023)  (0.643)  ( 0.001) ( 0.001) (0.007)
Family contact  −0.008 0.0509  0.197  0.1908  −0.0474
   (0.861)  (0.263)  ( 0.001) ( 0.001) (0.293)
Finances  −0.1021  −0.0162 0.1472  0.2062  −0.0923
   (0.022)  (0.716)  ( 0.001) ( 0.001) (0.036)
Health  −0.0449 0.0176  0.1516  0.277 −0.1409
   (0.313)  (0.692)  ( 0.001) ( 0.001) (0.001)
Job  −0.1595  −0.1257 0.0673  0.0824  −0.161
   (0.113)  (0.201)  (0.475)  (0.369)  (0.102)
Living situation  −0.1555  −0.0639 0.2466  0.2036  −0.1174
   ( 0.001) (0.149)  ( 0.001) ( 0.001) (0.007)
Safety  −0.1325  −0.0829 0.0963  0.1301  −0.0986
   (0.003)  (0.061)  (0.023)  (0.001)  (0.025)
Satisfaction with general life  −0.0563 0.0139  0.1602  0.2359  −0.1127
   (0.204)  (0.754)  ( 0.001) ( 0.001) (0.010)
Social relations  −0.0102 0.0545  0.1815  0.2698  −0.0387
 (0.823)  (0.230)  ( 0.001) ( 0.001) (0.391)
Abbreviations: ROMI, Rating of Medication Inﬂ  uences; ROMI Factor 1, 2, and 5: greater score indicates poorer compliance attitude; Factor 3 and 4: greater score indicates 
greater compliance attitude; QOLI, Quality of Life Interview; greater score in subjective subscales indicates greater level of functioning and satisfaction. Greater score in objective 
subscales indicates lower level of functioning, except in Family contact, Social contact, and Amount of money spent on self, where greater score indicates greater level of functioning.Patient Preferences and Adherence 2007:1 16
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group showed that patient perception of medication beneﬁ  t 
continued to improve for up to a year after treatment initiation 
and remained congruent with improvement in psychopathol-
ogy and quality of life over time.
A limitation of the study is that differences in the num-
ber and content of speciﬁ  c items in different versions of the 
ROMI make direct comparison of the 5 factors identiﬁ  ed 
from the 19 item ROMI in the current study with ROMI 
factors identiﬁ  ed in other studies somewhat difﬁ  cult. PCA 
analysis of the 7 compliance items and 13 noncompliance 
items of the original version of the ROMI scale developed 
by Weiden, yielded 3 compliance factors and 5 noncom-
pliance factors (Weiden et al 1994). Comparison of these 
factors to the factors identiﬁ  ed in our study is not possible 
since the speciﬁ  c ROMI items differed and our PCA analysis 
combined both compliance and noncompliance items. The 
5 factors derived from the ROMI items in the current study 
are largely consistent with a PCA analysis of the same 19 
item ROMI version used with a different patient population 
(Liu-Seifert et al 2007). In that study, 7 factors were identi-
ﬁ  ed, 4 of which directly correspond with factors identiﬁ  ed in 
the current analysis: perceived medication beneﬁ  t, positive 
external inﬂ  uence, denial of illness, and negative aspects of 
medication. In addition, the identiﬁ  ed factors are consistent 
with 4 constructed factors (need for treatment, beneﬁ  ts of 
medication, negative aspects of medication, and external 
support factors) based on a combined analysis of ROMI and 
the Insight and Treatment Attitudes Questionnaire (ITAQ) in 
ﬁ  rst episode schizophrenia patients (Perkins et al 2006).
An additional limitation of the present study was that 
it was a clinical trial and may not reﬂ  ect completely the 
real world patient treatment setting. The current study was 
designed to reﬂ  ect the usual clinical practice in the treatment 
of schizophrenia, including dosing according to clinician’s 
discretion, enrolling patients with comorbid conditions such 
as substance abuse and the open-label design. However, 
patients who are willing to enter a clinical trial might have 
different motivation and beliefs about treatment than patients 
in other settings. With these caveats, data from the present 
study may still provide useful information in developing 
interventions to improve patient treatment persistence and 
long-term prognosis.
Conclusions
Patient perception of an effective and beneﬁ  cial treatment 
was found to be the only signiﬁ  cant predictor of treatment 
persistence among the 5 underlying factors of medication 
influence. Effective treatment can maximize the 
beneﬁ  t-to-risk ratio and inﬂ  uence patient beliefs about the 
value of medication. Current ﬁ  ndings highlight the role of 
effective symptom control and patient perception of treatment 
efﬁ  cacy in medication persistence and may offer strategies 
for interventions to improve patient outcome.
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